Number of pages: 120 | Report Format: PDF | Published date: 28 January, 2022
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
The global preclinical imaging was pegged at ~US$ 3.25 billion in 2021 and is expected to witness a CAGR of ~3.8% during the forecast period.
Preclinical imaging is the visualization of living animals for research purposes specially in drug development. It is a multidisciplinary field comprising molecular biology, chemistry, computer science engineering and medicine. This imaging system can be broadly categorized into Primary morphological/ anatomical and primary molecular imaging techniques. Techniques such as high-frequency micro-ultrasound, magnetic resonance imaging (MRI) and computed tomography (CT) are generally used for anatomical imaging while optical imaging(fluorescence and bioluminescence), positron emission tomography (PET) and single photon emission computed tomography (SPECT) are typically used for molecular visualizations. Each imaging system has its own intrinsic advantages and limitations. Many manufacturers are supplying multi-modal systems which combines the advantages of anatomical modalities such as CT and MR with the molecular imaging of PET and SPECT. Preclinical imaging techniques comprise the reduction of biological inconsistency which fully obeys 3R (Replacement, Reduction, and Refinement) rules. The ability to acquire an imposing amount of exclusive information in distinct forms as well as a significant reduction in the number of animals required for a specific study.
The global preclinical imaging market is mainly driven by rising demand for noninvasive small-animal imaging techniques, growth opportunities in emerging markets and launch of technological advanced products. Similarly, increasing number of Clinical Research Organizations (CROs) and pharmaceutical companies are growing in adoption for in-vivo imaging systems in preclinical research, which is additionally expected to accelerate the development of preclinical imaging market. However, high installation costs, high operational costs, procedural limitations on animal testing with autonomous systems, and the requirement for clinical trial-based evidence are all expected to limit market growth to some extent.
The global preclinical imaging market has been analyzed from three perspective: Type and Region.
Preclinical Imaging Market by Type
On the basis of Market Type, Preclinical Imaging Market is segmented into modality, reagents, software and services. The modality segment is further categorized into optical imaging systems, micro-MRI, micro-PET, micro-SPECT, micro-CT, micro-ultrasound and others (magnetic particle imaging (MPI) system, photoacoustic (PAT) imaging, and multi-modal systems). The optical imaging systems are sub-segmented into bioluminescence/fluorescence imaging systems, standalone fluorescence imaging systems and optical + X-ray/optical + CT. Micro ultrasound is predictable to register for the leading markets share over forecasted period as it is a miniature version of ultrasound which ultimately has a wider range of applications in research activities for small animal models, which will boost the efficacy of the techniques Whereas, reagents segment is furthered categorized into preclinical optical imaging reagents, preclinical MRI contrast agents, preclinical nuclear imaging reagents, preclinical CT contrast agents and preclinical ultrasound contrast agents. The preclinical optical imaging reagents is sub-segmented into fluorescent imaging reagents and bioluminescent imaging reagents. The preclinical nuclear imaging reagents is sub-segmented into preclinical SPECT probes and preclinical PET Tracers. The preclinical MRI contrast agents is sub-segmented into gadolinium-based preclinical MRI contrast agents, iron-based preclinical MRI contrast agents. The preclinical CT contrast agents is sub-segmented into iodine-based preclinical CT contrast agents, barium-based preclinical CT contrast agents, gold nanoparticles and gastrografin-based preclinical CT contrast agents.
Preclinical Imaging Market by Region
Based on region, the global preclinical imaging market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). North America dominates the preclinical imaging market because of the presence of well-established players, technological advancements in the field of molecular imaging, rising market demand for non-invasive small-animal imaging techniques and increased funding for preclinical research within the region. This region recognizes many preclinical projects and the United States accommodates several private and public firms, both of which work in the market's favour. Asia-Pacific is expected to experience significant growth during the forecast period as a result of increasing funding to support preclinical research as well as the presence of well-established market players within the region. The inflexibility of the APAC market is due to the government's strong support for pharmaceutical and biotechnology R&D in the form of significant funds. Emerging investments in radioisotope production, an improving regulatory scenario across countries and an increase in translational research, all contribute to the market's regional value.
The market is extremely competitive and fragmented. Strategic initiatives such as product upgrades, portfolio diversification, regional expansions, fusions, and acquisitions are being implemented by market participants. Prominent players operating in the preclinical imaging market are PerkinElmer Inc., Bruker, FUJIFILM Visualsonics, Inc., Mediso USA, MILabs B.V., MR Solutions, Aspect Imaging, Tri-Modality Imaging, Inc., Miltenyi Biotec, Agilent Technologies, Inc., among others.